



BLOW UP YOUR GENOMICS WORKFLOW.

Automate nucleic acid QC and get on with your life sciences.

If sample QC takes you more than two minutes, it's too manual. Fragment Analyzer™ takes the job off your hands—streamlining lab operations and wiping out errors. Just pipette once and it delivers truly reliable results via automated capillary electrophoresis.

No chips. No tapes. No compromises.

- Setup in seconds
- Get resolution down to 2 base pairs
- Detection starts at 5 pg/μL

DITCH YOUR TIRED OLD WORKFLOW AT AATI-US.COM.



Discover 1% Somatic Mutation Detection from 10 ng DNA in 2 Hours

Accel-Amplicon™ Panels

Single-tube Multiplex Assays for Illumina® Platforms

- 2 Hour Workflow Sample to Sequencer
- 1% Mutant Allele Frequency Detection
- 10 ng Sample Input
- Validated for Circulating Cell-free DNA, FFPE, Fresh-frozen Samples

www.swiftbiosci.com




© 2015, Swift Biosciences, Inc. The Swift logo and Accel-Amplicon are trademarks of Swift Biosciences. Illumina is a trademark of Illumina, Inc. 15-0299, 05/15

Success is contagious

In 2011, Ion AmpliSeq™ technology enabled targeted sequencing from 10 ng of DNA or less. And the world responded.






In just four years we've designed over 25,000 custom panels for researchers around the world. With 10 ng of DNA or less, you can easily target sets of genes, and make sequencing a success for even old or degraded FFPE samples. Now that's an idea worth spreading.



AmpliSeq it. Because every sample matters.

Get more from your samples at thermofisher.com/ampliseq

ThermoFisher
SCIENTIFIC



2015-2016 SCIENTIFIC CONFERENCES

Presenting the most significant research on cancer etiology, prevention, diagnosis, and treatment

CRI-CIMT-EATI-AACR The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival
September 16-19, 2015 • New York, NY

Chromatin and Epigenetics in Cancer
Co-Chairpersons: Peter A. Jones, Sharon Y. R. Dent, and Charles W. M. Roberts
September 24-27, 2015 • Atlanta, GA

Advances in Breast Cancer Research
Co-Chairpersons: Matthew J. Ellis, Charles M. Perou, and Jane E. Visvader
October 17-20, 2015 • Bellevue, WA

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities
Co-Chairpersons: Kathleen R. Cho, Douglas A. Levine, and Benjamin G. Neel
October 17-20, 2015 • Orlando, FL

Fourth AACR International Conference on Frontiers in Basic Cancer Research
Chairperson: M. Celeste Simon
Co-Chairpersons: James P. Allison, John E. Dick, Nathanael S. Gray, and Victor E. Velculescu
October 23-26, 2015 • Philadelphia, PA

The Basic Science of Sarcomas
Co-Chairpersons: Robert G. Maki, Angelo Paolo Dei Tos, Jonathan A. Fletcher, Lee J. Helman, and Brian A. Van Tine
November 3-4, 2015 • Salt Lake City, UT

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Scientific Committee Co-Chairpersons: Levi A. Garraway, Lee J. Helman, and Jean-Charles Soria
November 5-9, 2015 • Boston, MA

Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship
Co-Chairpersons: Scott A. Armstrong, Charles G. Mullighan, Kevin M. Shannon, and Kimberly Stegmaier
November 9-12, 2015 • Fort Lauderdale, FL

New Horizons in Cancer Research: Bringing Cancer Discoveries to Patients Shanghai 2015
Co-Chairpersons: Lewis C. Cantley and Carlos L. Arteaga
November 12-15, 2015 • Shanghai, China

Eighth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
Co-Chairpersons: John M. Carethers, Marcia R. Cruz-Correa, Mary Jackson Scroggins, Edith A. Perez, Beti Thompson, and Cheryl L. Willman
November 13-16, 2015 • Atlanta, GA

Developmental Biology and Cancer
Co-Chairpersons: Hans Clevers, Stuart Orkin, and Suzanne Baker
November 30-December 3, 2015 • Boston, MA

Tumor Metastasis
Co-Chairpersons: Bruce R. Zetter, Melody A. Swartz, and Jeffrey W. Pollard
November 30-December 3, 2015 • Austin, TX

CSHA/AACR Joint Meeting: Big Data, Computation, and Systems Biology in Cancer
Conference Organizers: Andrea Califano, William C. Hahn, Satoru Miyano, and Xuegong Zhang
December 1-5, 2015 • Suzhou, China

EORTC-NCI-EMA-AACR International Conference on Biomarkers in Cancer Drug Development
Co-Chairpersons: Denis A. Lacombe and John W. Martens
December 3-4, 2015 • Brussels, Belgium

Noncoding RNAs and Cancer
Co-Chairpersons: Howard Y. Chang, Jeannie T. Lee, and Joshua Mendell
December 4-7, 2015 • Boston, MA

San Antonio Breast Cancer Symposium
Co-Directors: Carlos L. Arteaga, Virginia Kaklamani, and C. Kent Osborne
December 8-12, 2015 • San Antonio, TX

AACR-IASLC Joint Conference on Lung Cancer
Chairpersons to be announced
January 4-7, 2016 • San Diego, CA

The Function of Tumor Microenvironment in Cancer Progression
Co-Chairpersons: Raghu Kalluri, Robert A. Weinberg, Douglas Hanahan, and Morag Park
January 7-10, 2016 • San Diego, CA

Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic
Co-Chairpersons: Manuel Hidalgo, Hans Clevers, S. Gail Eckhardt, and Joan Seoane
February 11-14, 2016 • New Orleans, LA

10th AACR-JCA Joint Conference
Co-Chairpersons: Frank McCormick and Tetsuo Noda
February 16-20, 2016 • Maui, HI

AACR Annual Meeting 2016
Program Committee Chairperson: Scott Armstrong
April 16-20, 2016 • New Orleans, LA

Learn more and register at
www.AACR.org/Calendar

AACR American Association
for Cancer Research

FINDING CURES TOGETHERSM



Looking for A Genomic Research Partner?

Next-Generation Sequencing(NGS)

- Whole genome Sequencing (Hiseq X Ten)
- Exome Sequencing
- Targeted Sequencing
- Long Read Sequencing
- Transcriptome Analysis, small RNA
- Epigenomics

Bio Informatics

- Assembly / Mapping
- Variant (SNP / Indel) calling
- CNV & Breakpoints
- Expression Profiles
- DEGs / miRNA
- Enrichment Profiles
- Gene Annotation

Capillary Sequencing

Microarray

Oligonucleotide Synthesis

Genetically Engineered Mouse

Next-Gen Sequencing

Getting the most out of your single-cell RNA-seq data?

TRANSCRIPTOME ANALYSIS WITH NEXT-GEN SEQUENCING

Be confident using tools with the highest sensitivity and reproducibility



SMART-Seq™ v4 Ultra™ Low Input RNA Kit for Sequencing

Accurate, sensitive, single-cell mRNA-seq

The SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing, built on a combination of our experience and new LNA technology, is our most sensitive single-cell mRNA-seq kit. With direct cDNA synthesis from 1–1,000 intact cells (or 10 pg–10 ng of total RNA), mRNA-seq libraries generated from this kit outperform previously published protocols. We've used this kit to explore the differences and similarities between individual cells, showing the high-quality, consistent data that can be expected with the newest ultra-low input kit. Our continuous drive to improve our already best-in-class tools helps you push the frontiers of ultra-low input RNA-seq.

See more by visiting
www.clontech.com/single-cell-v4
or call 1.800.662.2566



Scan to find out more




Clontech Laboratories, Inc. • A Takara Bio Company
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)11.3904.6890 • Japan: +81.(0)77.543.7247
For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale. Takara and the Takara logo are trademarks of TAKARA HOLDINGS, Kyoto, Japan. Clontech, the Clontech logo, SMART-Seq, that's GOOD science!, and Ultra are trademarks of Clontech Laboratories, Inc. All other marks are the property of their respective owners. Certain trademarks may not be registered in all jurisdictions.
© 2015 Clontech Laboratories, Inc.

www.clontech.com 06.15 US (633648)



www.personalis.com/clinicaltrials



Tumor Genomic Profiling Services for Clinical Trials

Comprehensive Coverage, Tailored Results

Based on the Accuracy and Content Enhanced (ACE) platform, our advanced tumor profiling services provide the most complete genomic data from any tumor sample type. Our cancer panel includes coverage of over 1,300 genes, including clinically actionable genes, known driver mutations, immuno-oncology and key cancer pathway genes. Our service is tailored to address the needs of your clinical trial enrollment requirements while simultaneously making a broader research dataset available. As a result, we maximize the return on every tumor sample.

- ✓ DNA and RNA analysis from a single sample for maximum insight
- ✓ More coverage of key cancer pathway genes
- ✓ Alterations reported include SNVs, CNVs, gene fusions and low-level variant expression
- ✓ Comprehensive analysis with flexible reporting of the complete panel or a focused set of genes, depending on your requirements

www.personalis.com | info@personalis.com

+1 855-GENOME4 (436-6634)

+1 650-752-1300 (outside U.S.)



Personalis[®]
Pioneering Genome-Guided Medicine

Binuclease® 50ku \$58.00

Binuclease® (For the Digestion of DNA and RNA)

Binuclease is a genetically engineered endonuclease from *Serratia marcescens*. The enzyme is produced and purified from eukaryotic yeast cells, without contamination of endotoxin from prokaryotic cells. Functionally, this promiscuous nuclease digests all forms of DNA and RNA, including single stranded, double stranded, linear, circular and supercoiled DNA and RNA. The enzyme cleaves the phosphodiester bond of nucleic acids, producing 5' monophosphate terminated oligonucleotides 2-5 bases in length. The Binuclease is not a sequence dependent nuclease, capable of cleaving the phosphodiester bond at all positions among a nucleic acid chain. This promiscuous endonuclease is applied for removing nucleic acids in biological products. In the industry of vaccine, protein and saccharides pharmaceuticals, this endonuclease is widely used to get rid of nucleic acids, reducing the nucleic acid contaminant in the vaccines and protein products. This promiscuous nuclease is the ideal choice for viscosity reduction of cell lysate and cell culture clarification.

Mutant Proteinase K 100mg \$17.00

Mutant Proteinase K

The application of this Mutant Proteinase K is similar with wild type Proteinase K. But this mutant one has higher specific activity and more stable at room temperature. It is a non-specific serine proteinase with broad substrates. It is active over the pH range from 4 to 12. It can be used at any situation to digest native and denatured proteins. For instance, it is used for isolating mRNA or genomic DNA from different tissues and modifying glycoprotein for structure studies. Mutant Proteinase K is active with SDS, urea and EDTA and active between 15°C and 75°C.

Beijing SBS Genetech Co. Ltd.

Fax: +86-10-82784290

Email: order@sbsbio.com Website: www.sbsbio.com

Goodbye thermocycler.



Enjoy more playtime with **Recombinase Polymerase Amplification** (RPA) the isothermal enzymatic reaction that really works. RPA uses a recombinase-based process instead of thermocycling to amplify DNA, meaning **real-time detection within 15 minutes**.

Read over 40 RPA publications @
[twistdx.co.uk/publications](https://www.twistdx.co.uk/publications)

RPA. It really works.
twistdx.co.uk | +44 (0)1223 496700

Break free from qPCR

Find gene targets faster



Validating gene targets with qPCR is often slow and costly due to lengthy primer design, experimental assay optimization, and sample processing time.

QuantiGene® Plex Assays validate gene targets faster:

- No RNA purification or reverse transcription is required
- Multiplex panels of up to 80 genes are functionally validated
- One QuantiGene Plex® plate provides as much information as 20 qPCR plates



Download **"The 7 best reasons to break free from qPCR"**
www.ebioscience.com/breakfree-genres

Biology for a better world.

NORTH AMERICA: 888-999-1371 ■ EUROPE: +43 1 796 40 40-305 ■ JAPAN: +81 (0)3 6430 4020 ■ INQUIRIES: info@ebioscience.com

©2015 Affymetrix, Inc. All rights reserved. For Research Use Only. Not for use in diagnostic or therapeutic procedures.